Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.43 |
| ▸ | PARP11 | Q9NR21 | 3/20 | 0.43 |
| ▸ | PNMT | P11086 | 3/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CD44 | P16070 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6796232 | 0.88 | SRC (0.49) | PARP10PARP11PNMTHTR2CSRC | |
| Hydrochloric Acid SCHEMBL21598450 | 0.86 | SRC (0.47) | PARP10PARP11PNMTSRCMAPT | |
| SCHEMBL16599543 | 0.79 | TAAR1 (0.42) | PARP10PARP11PNMTPARP1PDPK1 | |
| SCHEMBL515124 | 0.74 | HTR5A (0.42) | PARP10PARP11PNMTPARP1PDPK1 | |
| SCHEMBL22926224 | 0.74 | PARP1 (0.39) | PARP10PARP11PNMTPARP1PDPK1 | |
| SCHEMBL108394 | 0.74 | PARP1 (0.43) | PARP10PARP11PNMTPARP1PDPK1 | |
| SCHEMBL13977384 | 0.74 | PARP1 (0.39) | PARP10PARP11PNMTPARP1PDPK1 | |
| SCHEMBL1870062 | 0.74 | PARP10 (0.43) | PARP10PARP11PNMTPARP1PDPK1 | |
| SCHEMBL5536927 | 0.74 | PARP1 (0.39) | PARP10PARP11PNMTPARP1PDPK1 | |
| SCHEMBL1119383 | 0.74 | CD44 (0.46) | PARP10PARP11PNMTPARP1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025229494-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-11-06 | — | — | WO | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| CN-117886810-A | Indoline compound and preparation method and application thereof | 徐州医科大学 | 2024-04-16 | — | — | CN | disclosed |
| CN-117003683-A | Synthesis method of indoline | 温州大学新材料与产业技术研究院 | 2023-11-07 | — | — | CN | disclosed |
| EP-4006014-B1 | PYRIMIDINE COMPOUND ACTING ON EGFR AND ERBB2 | CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| EP-4161494-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20220298135-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2022-09-22 | — | — | US | disclosed |
| US-8119683-B2 | Aryl substituted sulfonamide compounds and their use as anticancer agents | TAIPEI MEDICAL UNIVERSITY (TW) | 2012-02-21 | — | — | US | disclosed |
| US-20110039880-A1 | ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TAIPEI MEDICAL UNIVERSITY (TW) | 2011-02-17 | — | — | US | disclosed |
| US-20110039880-A1 | ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TAIPEI MEDICAL UNIVERSITY (TW) | 2011-02-17 | — | — | US | disclosed |
| US-20110039880-A1 | ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TAIPEI MEDICAL UNIVERSITY (TW) | 2011-02-17 | — | — | US | disclosed |
| WO-2011019634-A2 | ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TAIPEI MEDICAL UNIVERSITY (TW) | 2011-02-17 | — | — | WO | disclosed |
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2010-08-19 | — | — | US | disclosed |
| US-6869960-B2 | N-substituted spiropiperidine compounds as ligands for ORL-1 receptor | PFIZER INC. (US) | 2005-03-22 | — | — | US | disclosed |
| EP-1470126-A1 | N-SUBSTITUTED SPIROPIPERIDINE COMPOUNDS AS LIGANDS FOR ORL-1 RECEPTOR | PFIZER INC. (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20030158219-A1 | N-substituted spiropiperidine compounds as ligands for ORL-1 receptor | ITO FUMITAKA (JP) | 2003-08-21 | — | — | US | disclosed |
| WO-2003064425-A1 | N-SUBSTITUTED SPIROPIPERIDINE COMPOUNDS AS LIGANDS FOR ORL-1 RECEPTOR | PFIZER JAPAN INC. (JP) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158219-A1 | N-substituted spiropiperidine compounds as ligands for ORL-1 receptor | OGFRL1, OXER1, ORMDL3 | PARP10 3304/4885PARP11 2561/4885PNMT 3935/4885 |
| US-20110039880-A1 | ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | ARSA, SULT1E1, STS | PARP10 1251/4885PARP11 593/4885PNMT 3197/4885 |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, USP8, USP7 | PARP10 1807/4885PARP11 825/4885PNMT 4109/4885 |
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARD, PPARA | PARP10 1020/4885PARP11 739/4885PNMT 2576/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | PARP10 315/4885PARP11 160/4885PNMT 2333/4885 |
| US-20220298135-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | NPFFR2, NPFFR1, OPRL1 | PARP10 2394/4885PARP11 2873/4885PNMT 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.